Beijing, Beijing, China Legend Capital appeared to be the VC, which was created in 2001. The venture was found in Asia in China. The main office of represented VC is situated in the Beijing.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Legend Capital, startups are often financed by Qiming Venture Partners, Matrix Partners China, IDG Capital. The meaningful sponsors for the fund in investment in the same round are GGV Capital, Sequoia Capital China, SIG China (SIG Asia Investments). In the next rounds fund is usually obtained by GGV Capital, Tencent Holdings, Sequoia Capital China.
Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Beijing LaKala Billing Services, Renren Inc., Ucar We can highlight the next thriving fund investment areas, such as Information Technology, Pharmaceutical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. The fund has specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little.
The overall number of key employees were 8.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The typical startup value when the investment from Legend Capital is 500 millions - 1 billion dollars. The fund is constantly included in 7-12 investment rounds annually. The top amount of exits for fund were in 2018. Comparing to the other companies, this Legend Capital performs on 19 percentage points less the average number of lead investments. The real fund results show that this VC is 27 percentage points more often commits exit comparing to other companies.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Dearer Medical | 22 Jan 2024 | Minhang, Shanghai, China | |||
MacroLux | 15 Jan 2024 | Shenzhen, Guangdong, China | |||
Leapstack | $30M | 29 Dec 2023 | Shanghai, China | ||
Rhino Medical | $15M | 27 Dec 2023 | - | ||
Angitia Biopharmaceuticals | $46M | 19 Oct 2023 | Guangzhou, Guangdong, China | ||
Elios | $15M | 10 Oct 2023 | Shanghai, Shanghai, China | ||
Saige Research | $13M | 21 Sep 2023 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
HC Scientific | $46M | 28 Aug 2023 | Chengdu, Sichuan, China | ||
Wepure | $15M | 22 Aug 2023 | Guangzhou, Guangdong, China |
– Lynk Pharmaceuticals is a Hangzhou, China-based pharmaceutical R&D company.
– The company completed Series B financing of $50m.
– The round was led by Lilly Asia Ventures (LAV) with participation from New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) and its original shareholders Legend Capital and Med-Fine Capital.
– The new investment will be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline, expand international business, strengthen international collaborations with companies and support preclinical development of new projects.
– Berry Oncology Corporation, a member company of China’s leading early cancer screening firm Berry Genomics, closed a US$99.15m Series B1 financing round.
– This round was led by China Merchants Capital Management Co., Ltd. Existing investors Qiming Venture Partners and Legend Capital, along with new investors including Zhongjin Qichen Industry Equity Investment Fund, E Fund, Fujian Venture Investment Management Co., Ltd., Xiamen C&D Emerging Industry Equity Investment Co., Ltd. and other investors also participated.
– The new proceeds will enable the company to meet the demand for early cancer screening and diagnosis and boost its expansion in the market.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Dearer Medical | 22 Jan 2024 | Minhang, Shanghai, China | |||
MacroLux | 15 Jan 2024 | Shenzhen, Guangdong, China | |||
Leapstack | $30M | 29 Dec 2023 | Shanghai, China | ||
Rhino Medical | $15M | 27 Dec 2023 | - | ||
Angitia Biopharmaceuticals | $46M | 19 Oct 2023 | Guangzhou, Guangdong, China | ||
Elios | $15M | 10 Oct 2023 | Shanghai, Shanghai, China | ||
Saige Research | $13M | 21 Sep 2023 | Seoul, Seoul-t'ukpyolsi, South Korea | ||
HC Scientific | $46M | 28 Aug 2023 | Chengdu, Sichuan, China | ||
Wepure | $15M | 22 Aug 2023 | Guangzhou, Guangdong, China |
